Overview of Tracetate

Quick Facts

Property	Description
Active Ingredient	Megestrol acetate
Form	Oral suspension, Oral tablets
Pharmacological Class	Progestin, Antineoplastic agent, Appetite Stimulant
General Purpose	Palliative support, managing wasting syndrome
Origin	Synthetic derivative of progesterone

What Type of Medicine is Tracetate?

Tracetate is a prescription-only medication that contains megestrol acetate as its single active component. This substance is a synthetic derivative of the naturally occurring steroid hormone, progesterone, which gives it a strong influence over the body's hormonal systems. It is formally classified under three distinct pharmacological classes: a progestin, an antineoplastic agent, and an appetite stimulant. This triple classification reflects its established dual function in medical care, leveraging both hormonal modulation and metabolic effects. The compound's approval confirms its utility in managing select advanced medical conditions.

Composition and Available Forms

The medicine's composition is centered entirely on the megestrol acetate molecule, which is prepared for systemic effect via oral administration. The compound is supplied in two primary dosage forms to accommodate patient needs: a liquid oral suspension and conventional solid oral tablets. This provision of a liquid form is a key feature that often facilitates administration for patients facing conditions that complicate the intake of solid medication. Pharmacological data confirm that megestrol acetate is a highly potent progestational agent, underscoring its significant biological activity.

General Purpose and Action

The general purpose of Tracetate is to offer palliative support by intervening in both cellular growth and metabolic function. Its high-level action involves influencing the pathways of certain hormone-sensitive cells while also reliably promoting an increase in appetite and subsequent weight gain. This functionality is vital in scenarios such as counteracting the severe unexplained weight loss and cachexia (wasting syndrome) associated with chronic illness by supporting the patient's critical effort to stabilize or increase body mass.

Regulatory References

Megestrol - StatPearls - NCBI Bookshelf

What side effects are possible with Tracetate?

Possible Side Effects and Safety Information

Adverse reactions to megestrol acetate, the active component in Tracetate, are officially documented and classified by regulatory bodies, reflecting its hormonal and metabolic activity. The safety profile is structured to communicate the likelihood and nature of potential effects across various physiological systems.

Adverse Reaction Categories

Classification	Examples of Officially Documented Effects
Common	Weight gain, diarrhea, nausea, flatulence, headache, and hot flushes.
Uncommon	Thromboembolic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

The official classification of adverse reactions primarily involves the Gastrointestinal System, Metabolism and Nutrition, Vascular System, and Endocrine System.

Serious and Clinically Important Safety Notes

The regulatory label identifies two clinically significant safety concerns. The potential for thromboembolic events is documented, which pertains to the formation of blood clots. Additionally, a risk of adrenal suppression or insufficiency is noted, particularly in association with long-term, continuous, high-dose exposure.

Population and Duration-Related Safety

The medicine is officially contraindicated during pregnancy due to documented risks of fetal harm. Specific caution is required for patients with pre-existing diabetes mellitus due to the potential for glucose intolerance. The duration of use is relevant, as the risk of adrenal suppression is explicitly linked to chronic administration. Safety limitations officially include known hypersensitivity to the drug or components and caution in patients with a history of thrombotic disease.

This structured safety information ensures that all officially documented risks, from common occurrences to serious reactions, are systematically communicated.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the overdose profile for Tracetate (megestrol acetate) based on post-marketing reports and high-dose clinical studies.

Overdose manifestations reported in post-marketing surveillance have included a documented symptom profile featuring diarrhea, nausea, abdominal pain, shortness of breath (dyspnea), cough, unsteady gait, listlessness, and chest pain.

Required Emergency Actions

The regulatory guidance mandates that patients or caregivers seek immediate medical attention or call emergency services if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Contacting the poison control helpline is also advised.

Supportive Management

There is no specific antidote known for megestrol acetate overdose. Therefore, the official regulatory action is to take appropriate supportive measures. Clinical studies involving very high daily dosages, up to 1600 mg, did not result in unexpected serious side effects. However, due to the drug's excretion via the kidneys, the risk of toxic reactions may be greater in patients with impaired renal function, including the elderly, and monitoring renal function may be useful in these populations.

Therapeutic Uses of Tracetate

Tracetate (megestrol acetate) is commonly used to provide therapeutic support across two related clinical domains: supporting nutrition in patients experiencing wasting syndrome and offering palliative hormonal support for specific cancers. It is indicated for these primary uses.

Combatting Anorexia and Severe Wasting Syndrome

This domain addresses the severe, involuntary weight loss and profound anorexia (loss of appetite) that generally cluster together in conditions like advanced cancer and HIV/AIDS. Tracetate is applied in these contexts to support the patient's nutritional status. The core therapeutic role assists with appetite and is relevant for easing severe, involuntary weight loss, which supports maintaining functional stability. This intervention is commonly part of palliative support to maintain physical reserves and may support improved day-to-day comfort during challenging phases of chronic illness.

Palliative Endocrine Therapy for Advanced Cancers

Tracetate is generally used for the palliative management of advanced or recurrent breast cancer and endometrial cancer that are known to be hormone-sensitive. The medication is relevant for symptom management in hormone-sensitive tumor activity. This provides support that is relevant for easing the overall symptom load of the disease and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Nutritional Deficits

Category	Primary Benefit
Symptom Cluster	Severe anorexia, involuntary weight loss, cachexia
Therapeutic Role	Supports appetite and effort to stabilize body mass
Context of Use	Palliative support in advanced cancer or HIV/AIDS
Patient Benefit	Helps maintain physical reserves and overall comfort

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Uridine Triacetate

This medication is approved for the emergency treatment of severe or life-threatening toxicity caused by the chemotherapy agents fluorouracil or capecitabine, and its eligibility profile is defined by strict regulatory parameters.

Populations that Can Use the Medicine

Uridine Triacetate is authorized for use in both adult and pediatric patients who have experienced an overdose or early-onset, severe adverse reactions (e.g., severe gastrointestinal toxicity or neutropenia) following fluorouracil or capecitabine administration.

Populations that Cannot Use the Medicine

There are no absolute contraindications listed in the official prescribing information, meaning no conditions or populations strictly prohibit its use in the defined emergency setting.

Eligibility Restrictions

Classification	Status/Restriction
Timing Constraint	Treatment must be initiated within 96 hours of the end of fluorouracil or capecitabine administration. Use initiated after this window is not recommended.
Non-Emergency Use	The drug is not recommended for non-emergency treatment of adverse reactions.
Geriatric Patients	Sufficient data is lacking to determine if patients aged 65 and over respond differently from younger patients.
Hepatic/Renal Impairment	Specific eligibility rules or dose adjustments have not been established, as these patient populations have not been formally studied.

Pregnancy and Lactation

Limited human data is available regarding the risk to the fetus during pregnancy. For lactation, it is unknown whether the drug is present in human milk or what effects it may have on the breastfed infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding the interaction profile of Uridine Triacetate (Tracetate) indicates a limited scope of documented drug-drug and drug-food interactions.

Potential Pharmacokinetic Interactions

Interaction Type	Specific Information from Labeling
Transporter-Mediated	Uridine Triacetate is a weak substrate and inhibitor of the P-glycoprotein (P-gp) transporter in vitro. Due to expected high concentrations in the gut, an interaction with orally administered P-gp substrate drugs (e.g., Digoxin) cannot be ruled out, potentially leading to increased exposure of the substrate drug.
CYP450 Metabolism	The drug demonstrated no meaningful inhibitory or inducing effects on major CYP450 enzymes (such as CYP3A4, 1A2, 2D6, etc.) in in vitro studies. Clinically significant interactions based on major enzyme metabolism are not anticipated.
Contraindicated Combinations	No medicinal products are explicitly listed as absolutely contraindicated for co-administration in the official regulatory documents.

Food and Timing Interactions

Administration of Uridine Triacetate with food does not alter the overall rate or extent of exposure (AUC or Cmax) of the active moiety, uridine. Therefore, the drug may be administered without regard to meals. No specific requirements for dose separation or timing relative to other medicines are documented in the official labeling based on interaction studies.

Population Considerations

Official documents do not specify any unique drug-drug interaction concerns or constraints for specific patient populations, such as those with hepatic or renal impairment, within the interaction section.

Mechanism of Action

Tracetate functions as an inhibitor of the receptor activator of NF-kB ligand (RANKL), a critical cytokine that mediates the process of bone resorption. The drug achieves its effect by selectively binding to RANKL, thereby preventing its required interaction with the RANK receptor expressed on the surface of osteoclast precursors and mature osteoclasts. This blockade disrupts the cellular signaling necessary for osteoclast differentiation, activity, and survival. The resultant reduction in the number and function of active osteoclasts directly decreases the rate of bone resorption. This action modulates the overall bone remodeling cycle, shifting the balance in favor of bone formation processes, which contributes to the preservation of existing bone structure and bone mass.

Dosage and Administration Information

How Tracetate is Used — Official Administration Guidelines

Administration Scope

The official instructions for using Tracetate (megestrol acetate) define precise administration patterns that vary based on the medicine's concentration and the specific condition being addressed. The medicine is supplied for the exclusive Oral route of administration.

Category	Official Instruction
Dosing schedule	Wasting Syndrome: The recommended adult dose for the high-concentration 125 mg/mL oral suspension is 625 mg once daily. The standard 40 mg/mL suspension typically uses an 800 mg once-daily dose. Advanced Cancer: Doses for palliative use range from 40 mg to 320 mg per day for endometrial carcinoma and 160 mg per day for breast cancer.
Frequency and timing	The oral suspension for wasting syndrome is generally taken Once Daily. Tablet dosing for cancer treatment is often administered in divided doses throughout the day.
Preparation requirements	If using the oral suspension, the container must be shaken well before each measurement and administration.
Age-group rules	Geriatric Patients: Dose selection should be cautious, generally starting at the lower end of the dosing range due to the greater likelihood of reduced organ function. Pediatric Patients: Safety and effectiveness in this population have not been established.
Special procedural conditions	The high-concentration 125 mg/mL oral suspension is not interchangeable or substitutable with the standard 40 mg/mL concentration on a milligram-per-milligram basis.

Connection to the Overall Use Protocol

These official guidelines establish clear procedural rules that govern the use of the medicine across its different forms. The required dose and frequency are dictated by the specific clinical context. For cancer indications, efficacy is assessed only after a minimum of two months of continuous treatment. This structured approach, which includes strict adherence to product-specific instructions like proper suspension handling and respecting concentration differences, ensures the medicine is utilized exactly as documented.

Recent Clinical Evidence

Research evidence / Overview of studies for Tracetate

Evidence for use in Anorexia-Cachexia Syndrome and Weight Loss

The medicine was evaluated in research exploring its application in Anorexia-Cachexia Syndrome (ACS) and involuntary weight loss, which are conditions characterized by fluctuating or episodic manifestations related to appetite and metabolism. This evidence base consists primarily of Randomized Controlled Trials (RCTs) and comprehensive reviews that pooled data from these trials. The agent's role in research examining appetite loss and involuntary weight changes was evaluated in these settings.

Findings describe patterns observed in the studies where patients reported how symptoms evolved as an increase in appetite. Trials documented measurements of body weight increase. However, outcomes reflecting daily functioning or activity level—often called Quality of Life (QOL)—were mixed across the reported trials. Research provides insight that long-term effects are not fully established, and comparative evidence is lacking to fully clarify the results when assessed against other interventions.

Evidence for use as Palliative Endocrine Therapy in Advanced Cancers

The medicine was evaluated in research exploring a hormonal mechanism in conditions involving periods of heightened symptoms related to advanced or recurrent cancer. The medicine was evaluated in research exploring use in patients with hormone-sensitive breast cancer (primarily in postmenopausal women) and certain endometrial carcinomas.

These trials monitored disease-specific outcomes, such as the Objective Response Rate (ORR), which measures the frequency of tumor response. Researchers also explored Time to Progression (TTP) of the disease. Data show patterns related to the medicine's use as a palliative approach—meaning it focuses on managing the disease rather than curative intent—in these populations.

Long-Term Studies and Follow-up

The main research that led to the medicine's use was relevant in trials assessing short-term or episodic symptom patterns and often focused on defined time intervals of several weeks or months. This section summarizes that long-term effects are not fully established beyond these trial periods. The research did not establish whether patterns observed in the studies regarding weight or response are sustained over periods extending beyond the scope of the clinical trials. Data related to these areas of uncertainty are still emerging.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tracetate (FAQ)

Q: Does Tracetate need to be taken with food, or can it be taken on an empty stomach?

Official product information indicates that the high-concentration oral suspension of Tracetate can be taken without regard to meals (with or without food). However, the standard concentration of the oral suspension may have increased absorption when taken with food. Patients should follow the specific administration instructions provided by their prescriber.

Q: Do people typically experience stomach upset when they first start Tracetate?

Regulatory documents list several adverse effects involving the gastrointestinal system as common, including diarrhea, nausea, and flatulence. These are recognized as part of the medicine’s known safety profile and may be experienced when treatment is initiated.

Q: Is it normal to feel dizzy when starting Tracetate?

Dizziness has been reported as a possible side effect of Tracetate. Any new or worsening symptoms, including dizziness, should be discussed with the patient's healthcare provider.

Q: Is Tracetate a controlled substance?

Tracetate contains megestrol acetate, which is a synthetic derivative of the steroid hormone progesterone. It is a prescription-only medication but is not typically classified as a controlled substance under major governmental drug schedules.

Q: Does Tracetate affect blood pressure or heart rate?

Official prescribing information notes that adverse effects involving the cardiovascular system have been reported. These can include hypertension (high blood pressure) and palpitation (a feeling of a racing or pounding heart). Official prescribing information recommends caution for patients with pre-existing heart conditions.

Q: Can Tracetate cause skin rashes or allergic reactions?

The medicine is contraindicated (should not be used) in patients who have a known hypersensitivity to the drug or any of its components. Furthermore, skin rash and pruritus (itching) are listed as documented adverse events.

Q: What are the general rules for disposing of unused Tracetate?

Regulatory documents indicate the medicine should not be poured down a sink or toilet to prevent environmental release. For guidance on proper disposal of unused or expired medication, consulting a pharmacist or local waste disposal company is recommended.

Q: Can Tracetate cause changes in mood or behavior?

Adverse events involving the central Nervous System are documented, including reports of depression, confusion, and abnormal thinking. Any shifts in mood or behavior should be discussed with the patient's healthcare provider.

Q: Is the effectiveness of Tracetate affected by age or gender?

Regarding age, dose selection for older adults generally requires caution. This is primarily due to the greater likelihood of reduced kidney or liver function in this population, rather than a direct change in drug effectiveness. Official sources do not provide a definitive statement on the effect of gender on the medicine's overall effectiveness.

Q: What information should I tell my doctor before starting Tracetate?

It is important for patients to inform their doctor about all pre-existing conditions. It is especially important to mention diabetes mellitus, a history of thrombotic disease (blood clots), and if they are or may become pregnant, as these require specific caution or rule out use.

Q: Can taking Tracetate make you feel tired or fatigued?

Tiredness, also known as asthenia, is sometimes reported as a possible side effect listed in official safety information for the medicine.

Q: What happens if a dose of Tracetate is missed?

General patient guidance suggests that if a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped. Official guidance notes that patients should not take a double dose to make up for a missed one. Specific instructions from the prescriber should always be followed.

Q: How long does the average course of Tracetate treatment last?

For specific cancer indications, official guidelines note that effectiveness is assessed only after a minimum of two months of continuous treatment. The full duration of therapy for any indication is determined by the treating physician based on the specific condition and the patient’s response.

Q: Does Tracetate need to be taken at a specific time of day?

The oral suspension form is typically prescribed to be taken once daily. To aid adherence, it is common practice to take the dose at the same time each day, although the specific time is flexible.

Q: Is it true that Tracetate can affect sleep patterns?

Yes, difficulties with falling asleep or staying asleep (referred to as insomnia) are listed in official documents as a possible side effect of the medicine.

Q: How often do the side effects of Tracetate occur in users?

Side effects are officially categorized by their frequency. For example, effects like weight gain, diarrhea, and nausea are listed as common occurrences, while more severe events like thromboembolic events (blood clots) are classified as uncommon.

Q: How long does Tracetate stay in your system after the last dose?

The time it takes for half of the medicine to be eliminated from the body (the half-life) is approximately 20 to 50 hours for the oral suspension. Most of the medicine is cleared from the body, primarily through urine and feces, within 10 days of the last dose.

Q: Is Tracetate known to cause weight gain or weight loss?

Weight gain is explicitly listed as a common adverse reaction in the official safety information. The medicine is, in fact, indicated for the clinical purpose of increasing appetite and promoting weight gain in patients dealing with wasting syndrome.

Q: How quickly should I expect Tracetate to start working?

Clinical trials for appetite stimulation showed that increases in caloric intake and weight stabilization were typically documented over treatment periods lasting several weeks, such as 12 weeks. While a change in appetite may be noticed sooner, the full therapeutic response is assessed over a period of weeks to months.

Q: Can Tracetate be used by children, and if so, at what age?

Official regulatory documents clearly state that the safety and effectiveness of Tracetate in pediatric patients have not been established. Decisions regarding the use and management of Tracetate in pediatric patients are made by the treating physician.

How should Tracetate be stored and disposed of?

Tracetate (megestrol acetate oral suspension) must be stored at controlled room temperature, specifically between 15 and 25 C (59 and 77 F). The container must be kept tightly closed and protected from excess heat. To ensure proper drug stability, it is required that the bottle be shaken well before using each time. The medication must be stored out of reach of children and locked up due to potential toxicity. To dispose of Tracetate, follow the guidelines provided by your pharmacist or local waste disposal programs. It should not be poured down a sink or toilet (flushed), and care must be taken to avoid environmental release, adhering to all applicable local and national regulations.

Tracetate